Method of Increasing Efficacy of Tumor-Cell Killing Using Combinations of Anti-Neoplastic Agent
Through use of the present invention, ineffective treatment regimens can be avoided in certain sub-populations of patients suffering from neoplastic diseases, effective treatment regimens can be instituted for patients who were previously refractive to certain treatments, and an overall improvement in anti-neoplastic therapies can be achieved.
Researchers at UC San Diego have developed a method of improving the killing efficacy of treatments for neoplasias using CD33-binding agents. This technology achieves the improvement by treating a patient with a substance that increases the amount of active Syk protein and/or SHP-l protein in the target neoplastic cells before or during treatment with an agent that specifically binds the CD33 protein.
Patent Number: US7977320B2
Application Number: US2007718127A
Inventor: Ball, Edward D. | Balaian, Larissa
Priority Date: 29 Oct 2004
Priority Number: US7977320B2
Application Date: 30 Jul 2007
Publication Date: 12 Jul 2011
IPC Current: A01N004304 | A61K003170
US Class: 514043 | 514042 | 514045 | 514049
Assignee Applicant: The Regents of the University of California
Title: Method of increasing efficacy of tumor cell killing using combinations of anti-neoplastic agents
Usefulness: Method of increasing efficacy of tumor cell killing using combinations of anti-neoplastic agents
Summary: For increasing efficacy of cell-killing agent useful for treating neoplasia e.g. leukemia such as acute myeloid leukemia (AML) (claimed).
Disease Diagnostic/Treatment
Cancer/Tumor
7977320
Intellectual Property Info Patented technology (U.S. patent application, published 20-Mar-2008 (2008/0069818), includes the following allowed claims: A method of increasing the efficacy of a cell-killing agent on a neoplastic cell that expresses CD33, said method comprising: exposing the neoplastic cell to a substance that increases the amount of functional Syk protein kinase, SHP-1 protein phosphatase, or both, in the neoplastic cell, determining the presence or activity level of said Syk protein, SHP-1 protein, or both in said neoplastic cell in response to the exposure, wherein the presence or level of active Syk protein, SHP-1 protein, or both is indicative of a likelihood of successful treatment of a neoplasia with said cell-killing agent, and recommending administering a therapeutically effective amount of said cell-killing agent based upon the determination of the presence or activity of said Syk protein, SHP-1 protein, or both in said neoplastic cell, thereby increasing the efficacy of the cell-killing agent on the neoplastic cell. A method of treating a neoplasia, said method comprising: administering at least one substance that increases the amount of functional Syk protein kinase, SHP-1 protein phosphatase, or both, in at least one cell of the neoplasia, determining the presence or activity level of said Syk protein kinase, SHP-1 protein phosphatase, or both, in said neoplastic cell in response to administration of said substance to said cell; and providing information about the determination for clinical administration of a therapeutically effective amount of at least one cell-killing agent based upon the presence or activity of said Syk protein, SHP-1 protein, or both in said neoplastic cell. A method of treating a patient for a neoplasia characterized by cells that express CD33, said method comprising: obtaining the amount or activity state of the Syk protein kinase, SHP-1 protein phosphatase, or both, in at least one neoplastic cell of the neoplasia, and providing a treatment regimen based on the amount or activity state that is determined for clinical administration of a therapeutically effective amount of a cell-killing agent that targets CD33 based upon the amount or activity state of the Syk protein kinase, SHP-1 protein phosphatase, or both, in said neoplastic cell of the neoplasia. Tech ID/UC Case 21417/2005-062-0 Related Cases 2005-062-0
USA
